Acurion, a San Diego, CA-based precision oncology technology company, has closed on $4.3 million in seed financing led by TK & Partners.
The round also saw participation from Mesa Verde Venture Partners, the National Foundation for Cancer Research, the Asian Fund for Cancer Research, Bootstrap Ventures, institutional investors, impact funds, and healthcare executives.
The company plans to use the funds for clinical validation, platform development, regulatory preparation, and the launch of OncoGaze™ for broader clinical and research use.
Acurion’s technology is based on the work of co-founder and Chief Scientific Officer Ludmil Alexandrov, PhD, a professor at UC San Diego, whose research on mutational signatures has changed how we understand cancer and its treatment.
Read More:Court Square Capital Partners Acquires Majority Stake in CallTower
The company has reached important milestones, including publishing in top scientific journals, growing partnerships with clinics, and connecting with industry leaders.
“We’re moving fast from validation to use,” said Fultz. “Our focus is now on meeting clinical and regulatory goals and putting this technology in the hands of doctors who can use it.”
“This funding shows strong confidence in our technology and mission,” said Rick Fultz, CEO of Acurion. “The future of precision oncology depends on making advanced biomarker detection accessible, scalable, and practical for real world clinical use. This investment helps us speed up development and bring our technology closer to helping cancer patients.”
“Acurion stood out right away for tackling a global problem with a strong technical edge, an exceptional team, and a clear plan,” said Tomas Koch, Chairman of TK & Partners.
“AI can transform how we detect and act on cancer biomarkers,” said Carey Ng, PhD, Managing Partner at Mesa Verde Venture Partners. “Acurion impressed us with its ability to turn complex science into a solution that fits smoothly into existing clinical workflows, making precision oncology more widely accessible.”
About Acurion
Founded in 2021 by Ludmil B. Alexandrov, PhD, François Ferre, PhD, Scott M. Lippman, M.D., Magda Marquet, PhD, and Webster Cavenee, PhD, Acurion is a San Diego-based precision oncology company developing AI-powered tools to detect biomarkers from standard pathology images. Unlike genomic tests that require additional tissue or specialised testing, Acurion’s OncoGaze™ platform provides insights directly from routine pathology slides, making precision medicine faster, more scalable, and more accessible.
Many cancer patients still face delays or lack access to biomarker testing despite advances in targeted therapies. Acurion aims to improve access to precision oncology by enhancing biomarker detection and guiding treatment decisions for multiple advanced cancer types.
Read More:Numos Raises $4.25M in Seed Funding
